Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan

The combination of weekly topotecan and gemcitabine is well tolerated, but best response rate is 17%, and confirmed response is only 9%, which is not significantly better than single agent gemcitabine or topotecan. These results do not provide compelling evidence for the combination of weekly gemcitabine and topotecan as a promising therapy.